Biotest AG / Disposal 23.10.2009 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Biotest agrees to sell its Medical Diagnostics business to Bio-Rad Dreieich, 23 October 2009. Biotest AG announced today that it has signed an agreement to sell major parts of its Medical Diagnostics segment to Bio-Rad Laboratories, Inc. (Hercules, CA/USA), a multinational manufacturer and distributor of life science research and clinical diagnostic products. The transaction is subject to certain closing conditions, including merger approval, and is expected to close in the first quarter of 2010. According to the terms of the transaction, Bio-Rad will acquire all shares of Biotest Medical Diagnostics GmbH (Dreieich) and Biotest Diagnostics Corporation (Rockaway/USA). In addition, the transaction comprises the transfusion and transplantation diagnostic businesses of Biotest Group's international subsidiaries under an asset deal. The purchase price amounts to EUR45 million. In the first half of 2009, the Medical Diagnostic activities to be sold achieved sales of approx. EUR21 million and contributed about 9% to the Biotest Group revenue. With the planned disposal, the Biotest Group intends to sharpen its focus on developing and marketing innovative pharmaceutical and biotherapeutic drugs in immunology and haematology. Biotest Aktiengesellschaft The Executive Management Board Biotest AG Landsteinerstr. 5 D-63303 Dreieich www.biotest.de Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest is a provider of pharmaceutical and biotherapeutic drugs as well as reagents and systems for diagnostics and microbiology. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of application of immunology and haematology. In its Plasma Protein segment, Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. The products of the Microbiological Monitoring segment are primarily used in hygiene monitoring, while those of Medical Diagnostics are used, for example, in blood transfusions and transplants. Biotest has more than 2,000 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange. Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 Securities' ID No., ISIN preference shares: 522723, DE0005227235 Listing: Prime Standard/Official traded Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart 23.10.2009 |[![CDATA[|[a href="http://www.dgap.de"|]Financial News transmitted by DGAP|[/a|]]]|] --------------------------------------------------------------------------- Language: English Company: Biotest AG LandsteinerstraÃe 5 63303 Dreieich Deutschland Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Biotest AG: Biotest agrees to sell its Medical Diagnostics business to Bio-Rad
| Source: EQS Group AG